Daniel De Carvalho
Sites: CDL-Toronto, CDL-Vancouver
Dr. Daniel De Carvalho is a renowned expert in cancer epigenomics and leads a research group at the Princess Margaret Cancer Centre and University of Toronto. He is a pioneer in the use of cancer epigenetics combined with advanced computational approaches for developing novel liquid biopsy tools applied to cancer early detection, classification and monitoring therapy response.
Dr. De Carvalho has published over 80 high-profile research papers, many of those featured in prestigious scientific journals such as Nature, Science, Cell, Nature Medicine, Cancer Cell, among others, and was an invited speaker to over 150 talks worldwide, including such prestigious venues as the opening plenary lecture at AACR annual meeting. For his scientific contributions, Dr. De Carvalho received numerous awards, including the AACR-Waun Ki Hong Award, Canadian Cancer Society Bernard and Francine Dorval Prize and the Canadian Institutes of Health Research (CIHR) Early Career Award in Cancer. He received the Canada Research Chair in Cancer Epigenetics, the Helen M. Cooke Endowed Professorship and was elected membership in the 2019 cohort of The Royal Society of Canada.
Dr. De Carvalho founded and currently serves as CSO of Adela, a biotech company developing cell-free DNA methylation liquid biopsy technology for cancer early detection, classification and monitoring therapy response.